Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

The Northwest Coalition for Primary Care Practice Support
The Northwest Coalition for Primary Care Practice Support
Status: Enrolling
Updated:  10/11/2017
GroupHealthCoop
mi
from
Seattle, WA
The Northwest Coalition for Primary Care Practice Support
The Northwest Coalition for Primary Care Practice Support
Status: Enrolling
Updated: 10/11/2017
GroupHealthCoop
mi
from
Seattle, WA
Click here to add this to my saved trials
Treatment of Supine Hypertension in Autonomic Failure
The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure
Status: Enrolling
Updated:  10/12/2017
Vanderbilt University
mi
from
Nashville, TN
Treatment of Supine Hypertension in Autonomic Failure
The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure
Status: Enrolling
Updated: 10/12/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Culturally Tailoring a Stroke Intervention in Community Senior Centers
Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers
Status: Enrolling
Updated:  10/12/2017
St. Barnabas Senior Services
mi
from
Los Angeles, CA
Culturally Tailoring a Stroke Intervention in Community Senior Centers
Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers
Status: Enrolling
Updated: 10/12/2017
St. Barnabas Senior Services
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Culturally Tailoring a Stroke Intervention in Community Senior Centers
Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers
Status: Enrolling
Updated:  10/12/2017
Watts Labor Community Action Committee
mi
from
Watts, CA
Culturally Tailoring a Stroke Intervention in Community Senior Centers
Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers
Status: Enrolling
Updated: 10/12/2017
Watts Labor Community Action Committee
mi
from
Watts, CA
Click here to add this to my saved trials
Culturally Tailoring a Stroke Intervention in Community Senior Centers
Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers
Status: Enrolling
Updated:  10/12/2017
Chinatown Service Center
mi
from
Los Angeles, CA
Culturally Tailoring a Stroke Intervention in Community Senior Centers
Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers
Status: Enrolling
Updated: 10/12/2017
Chinatown Service Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Culturally Tailoring a Stroke Intervention in Community Senior Centers
Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers
Status: Enrolling
Updated:  10/12/2017
Mexican American Opportunity Foundation
mi
from
Montebello, CA
Culturally Tailoring a Stroke Intervention in Community Senior Centers
Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers
Status: Enrolling
Updated: 10/12/2017
Mexican American Opportunity Foundation
mi
from
Montebello, CA
Click here to add this to my saved trials
Melatonin Supplements for Improving Sleep in Individuals With Hypertension
Melatonin Supplementation in Hypertensive Patients
Status: Enrolling
Updated:  10/13/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Melatonin Supplements for Improving Sleep in Individuals With Hypertension
Melatonin Supplementation in Hypertensive Patients
Status: Enrolling
Updated: 10/13/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Patient-Provider Communication and Medication Adherence
Racial Differences in Patient-Provider Communication and Medication Adherence
Status: Enrolling
Updated:  10/16/2017
Bellevue Hospital Ambulatory Care Practive
mi
from
New York, NY
Patient-Provider Communication and Medication Adherence
Racial Differences in Patient-Provider Communication and Medication Adherence
Status: Enrolling
Updated: 10/16/2017
Bellevue Hospital Ambulatory Care Practive
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading
Gonadal Steroid Regulation of the Natriuretic Peptide System
Status: Enrolling
Updated:  10/17/2017
Massachusetts General Hospital
mi
from
Boston, MA
Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading
Gonadal Steroid Regulation of the Natriuretic Peptide System
Status: Enrolling
Updated: 10/17/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
Effects of Nebivolol on Left Ventricular and Left Atrial Morphodynamics in Adults With Hypertension and Isolated Diastolic Dysfunction
Status: Enrolling
Updated:  10/19/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
Effects of Nebivolol on Left Ventricular and Left Atrial Morphodynamics in Adults With Hypertension and Isolated Diastolic Dysfunction
Status: Enrolling
Updated: 10/19/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Pranayama Breathing and Uncontrolled Hypertension
Take a Deep Breath: Randomized Controlled Trial of the Effects of Breathing Exercises on Blood Pressure
Status: Enrolling
Updated:  10/20/2017
University Of Missouri-Columbia
mi
from
Columbia, MO
Pranayama Breathing and Uncontrolled Hypertension
Take a Deep Breath: Randomized Controlled Trial of the Effects of Breathing Exercises on Blood Pressure
Status: Enrolling
Updated: 10/20/2017
University Of Missouri-Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
University of Alabama
mi
from
Birmingham, AL
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
Contra Costa Health Services (East and West Contra Costa)
mi
from
Martinez, CA
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
Contra Costa Health Services (East and West Contra Costa)
mi
from
Martinez, CA
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
Southeast Health Center
mi
from
San Francisco, CA
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
Southeast Health Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
Santa Clara Health Center
mi
from
San Jose, CA
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
Santa Clara Health Center
mi
from
San Jose, CA
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
Yale Primary Care Center
mi
from
New Haven, CT
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
Yale Primary Care Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
East Baltimore Medical Center
mi
from
Baltimore, MD
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
East Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
Boston Healthcare for the Homeless Program
mi
from
Boston, MA
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
Boston Healthcare for the Homeless Program
mi
from
Boston, MA
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
Montefiore Transition Clinic
mi
from
New York, NY
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
Montefiore Transition Clinic
mi
from
New York, NY
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
Medicine in Psychiatry Service clinic of the University of Rochester Medical Center
mi
from
Rochester, NY
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
Medicine in Psychiatry Service clinic of the University of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
Corporacion SANOS
mi
from
Caguas,
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
Corporacion SANOS
mi
from
Caguas,
Click here to add this to my saved trials
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated:  10/23/2017
Morningside Clinic
mi
from
New York, NY
Linking Former Inmates to Primary Care
Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care
Status: Enrolling
Updated: 10/23/2017
Morningside Clinic
mi
from
New York, NY
Click here to add this to my saved trials
Community Health Workers Using Patient Stories to Support Hypertension Management
Community Health Workers Using Patient Stories to Support Hypertension
Status: Enrolling
Updated:  10/23/2017
Lowell Community Health Center
mi
from
Lowell, MA
Community Health Workers Using Patient Stories to Support Hypertension Management
Community Health Workers Using Patient Stories to Support Hypertension
Status: Enrolling
Updated: 10/23/2017
Lowell Community Health Center
mi
from
Lowell, MA
Click here to add this to my saved trials
Community Health Workers Using Patient Stories to Support Hypertension Management
Community Health Workers Using Patient Stories to Support Hypertension
Status: Enrolling
Updated:  10/23/2017
Family Health Center of Worcester
mi
from
Worcester, MA
Community Health Workers Using Patient Stories to Support Hypertension Management
Community Health Workers Using Patient Stories to Support Hypertension
Status: Enrolling
Updated: 10/23/2017
Family Health Center of Worcester
mi
from
Worcester, MA
Click here to add this to my saved trials
Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
Nebivolol and Endothelial Regulation of Fibrinolysis
Status: Enrolling
Updated:  10/24/2017
UC-Boulder Clinical and Translational Research Center
mi
from
Boulder, CO
Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
Nebivolol and Endothelial Regulation of Fibrinolysis
Status: Enrolling
Updated: 10/24/2017
UC-Boulder Clinical and Translational Research Center
mi
from
Boulder, CO
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
San Francisco, CA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Aurora, CO
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Miami, FL
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Orlando, FL
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Louisville, KY
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Durham, NC
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Cleveland, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Columbus, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Portland, OR
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Nashville, TN
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Dallas, TX
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Falls Church, VA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Falls Church, VA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
mi
from
Mar del Plata,
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
mi
from
Mar del Plata,
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Via Christi Clinic
mi
from
Wichita, KA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Via Christi Clinic
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Columbia University Medical Center
mi
from
New York, NY
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Chinle Comprehensive Health Care Facility
mi
from
Chinle, AZ
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Chinle Comprehensive Health Care Facility
mi
from
Chinle, AZ
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Tsehootsooi Medical Center
mi
from
Fort Defiance, AZ
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Tsehootsooi Medical Center
mi
from
Fort Defiance, AZ
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Kayenta Health Center
mi
from
Kayenta, AZ
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Kayenta Health Center
mi
from
Kayenta, AZ
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Crownpoint Health Center Facility
mi
from
Crownpoint, NM
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Crownpoint Health Center Facility
mi
from
Crownpoint, NM
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Gallup Indian Medical Center
mi
from
Gallup, NM
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Gallup Indian Medical Center
mi
from
Gallup, NM
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Northern Navajo Medical Center
mi
from
Shiprock, NM
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Northern Navajo Medical Center
mi
from
Shiprock, NM
Click here to add this to my saved trials
Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention
Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention
Status: Enrolling
Updated:  11/1/2017
Davita Detroit Kresge Hemodialysis Unit
mi
from
Detroit, MI
Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention
Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention
Status: Enrolling
Updated: 11/1/2017
Davita Detroit Kresge Hemodialysis Unit
mi
from
Detroit, MI
Click here to add this to my saved trials